Lyell Immunopharma holder sells 10 common shares

Innovative Cellular Therapeutics Holdings Ltd, a ten percent owner of Lyell Immunopharma, Inc., reported a sale of 10 shares of common stock on July 17, 2026 at $13.70 per share.

Rhea-AI Filing Summary

Innovative Cellular Therapeutics Holdings Ltd, a ten percent owner of Lyell Immunopharma, Inc., reported a sale of 10 shares of common stock on July 17, 2026 at $13.70 per share. The filer indicated the trade was made under a Rule 10b5-1 trading plan. After this transaction, it directly beneficially owns 2,857,480 shares of Lyell common stock.

Insider Trade Summary 10b5-1

Net Seller: 10 shares

Net Sell 1 txn

Insider Innovative Cellular Therapeutics Holdings Ltd

Role 10% Owner

Sold 10 shs ($137.00)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	10	$13.70	$137.00

Holdings After Transaction: Common Stock — 2,857,480 shares (Direct)

Footnotes (1)

1. F1. Reflects 2,857,490 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 10 shares sold.

Key Figures

Shares sold: 10 shares Sale price per share: $13.70 Shares held after transaction: 2,857,480 shares +1 more

4 metrics

Shares sold 10 shares Common stock sale reported on July 17, 2026

Sale price per share $13.70 Price for the 10 LYEL common shares sold

Shares held after transaction 2,857,480 shares Direct beneficial ownership following the sale

Shares before transaction 2,857,490 shares Beneficially owned immediately prior to the reported sale

Key Terms

Rule 10b5-1 trading plan, beneficially owned, ten percent owner

3 terms

Rule 10b5-1 trading plan regulatory

"The filer indicated the trade was made under a Rule 10b5-1 trading plan."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

beneficially owned financial

"Reflects 2,857,490 shares of Common Stock beneficially owned by the Reporting Person immediately prior"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

ten percent owner regulatory

"The reporting person is identified as a ten percent owner of Lyell Immunopharma, Inc."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LYEL report for July 17, 2026?

Lyell Immunopharma (LYEL) reported that Innovative Cellular Therapeutics Holdings Ltd sold 10 shares of LYEL common stock on July 17, 2026 at $13.70 per share under a Rule 10b5-1 trading plan.

How many LYEL shares did Innovative Cellular Therapeutics sell and at what price?

Innovative Cellular Therapeutics sold 10 LYEL common shares at a price of $13.70 per share. This was reported as a sale transaction in common stock by a ten percent owner of Lyell Immunopharma.

How many LYEL shares does the reporting holder own after this Form 4?

Following the reported sale, Innovative Cellular Therapeutics beneficially owns 2,857,480 shares of Lyell Immunopharma common stock. A footnote explains this reflects 2,857,490 shares before the trade, less the 10 shares sold.

Was the LYEL insider trade made under a Rule 10b5-1 plan?

Yes. The filing’s Rule 10b5-1 checkbox indicates the 10-share sale of LYEL common stock was conducted under a Rule 10b5-1 trading plan, meaning it followed a pre-arranged trading instruction.

Who is the reporting person on this LYEL Form 4 and what is their status?

The reporting person is Innovative Cellular Therapeutics Holdings Ltd, identified in the filing as a ten percent owner of Lyell Immunopharma, Inc., reporting a direct ownership position in LYEL common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/20/2026 - 02:55 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Innovative Cellular Therapeutics Holdings Ltd

(Last) (First) (Middle)

190 ELGIN AVENUE

(Street)

GEORGE TOWN KY1-9008

(City) (State) (Zip)

CAYMAN ISLANDS

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lyell Immunopharma, Inc. [ LYEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/17/2026	07/17/2026	S		10	D	$13.7	2,857,480(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects 2,857,490 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 10 shares sold.

	Innovative Cellular Therapeutics Holdings Limited By: /s/ Lei Xiao Name: Lei Xiao Title: Chief Executive Officer	07/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)